Recent Presentations and Posters

American Rhinologic Society Annual Meeting – September 2023

Evaluation of LYR-220 corticosteroid matrices at week 24 from the BEACON study in CRS
Brent Senior, MD, FARS

Impact of LYR-210 Corticosteroid Matrices on the Incidence of Acute Exacerbations of Chronic Rhinosinusitis in Patients From the LANTERN Randomized Controlled Study


Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study.
Cervin A, Rimmer J, Wrobel A, Abelak Y, Brayton L, Kuang Y. International Forum of Allergy & Rhinology, 2021; 1- 13.

Impact of long-acting implantable LYR-210 corticosteroid matrices on quality of life of patients with chronic rhinosinusitis in the LANTERN study.
Rimmer, J, Cervin, A, Wrobel, A, et al. Int Forum Allergy Rhinol. 2023; 1- 4.

Pharmacokinetic Evidence of Steady and Sustained Drug Release from Long-Acting Implantable Corticosteroid Matrices for Chronic Rhinosinusitis.
Ow RA, Shotts S, Kakarlapudi V, et al. American Journal of Rhinology & Allergy, June 2022. doi:10.1177/19458924221107200

Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis.
Douglas RG, Psaltis AJ, Rimmer J, Kuruvilla T, Cervin A, and Kuang Y. International Forum of Allergy & Rhinology, Vol. 9, No. 4, April 2019.

Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses.
You C, Tseng L-F, Pappas A, Concagh D, Kuang Y. American Journal of Rhinology & Allergy, August 2021. doi:10.1177/19458924211039197

The development of bioresorbable composite polymeric implants with high mechanical strength.
Sharma U, Concagh D, Core L, Kuang Y, You C, Pham Q, Zugates G, Busold R, Webber S, Merlo J, Langer R, Whitesides George M, and Palasis M. Nature Materials, 17: 96-103, 2017.

Back to Top